Systemic amiloride inhibits experimentally induced neovascularization. Arch Ophthalmol 1990 Oct;108(10):1474-6
Date
10/11/1990Pubmed ID
1699514DOI
10.1001/archopht.1990.01070120122041Scopus ID
2-s2.0-0025130655 (requires institutional sign-in at Scopus site) 51 CitationsAbstract
Amiloride is an inhibitor of urokinase-type plasminogen activator, and might therefore have an inhibitory effect on neovascularization. Neovascularization was induced in rabbit corneas via local implantation of prostaglandin E1 pellets prepared in a slow-release polymer. Animals received daily intraperitoneal injections of 30 mg of amiloride, or an equivalent volume of saline solution for 5 days; both were well tolerated without severe untoward effect. Neovascular response, as documented by corneal photographs, was evaluated after 5 days of injections. The area of induced corneal neovascularization was decreased by 55% in animals receiving amiloride when compared with controls. Thus, amiloride and similar compounds may prove useful in the study and management of neovascularization.
Author List
Avery RL, Connor TB Jr, Farazdaghi MAuthor
Thomas B. Connor MD Professor in the Ophthalmology and Visual Sciences department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AlprostadilAmiloride
Animals
Cornea
Disease Models, Animal
Neovascularization, Pathologic
Photography
Rabbits